AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
mitotane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antineoplastics, nucleotoxic agents | 1820 | 53-19-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,MAP3K7,MAPK10,MAPK7,MAPK9,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PRKDC,SIK2,STK33,TEK,TTK | 30 | |||
| kinase-selectivity-class | AKT3,AXL,GRK2,PDK4 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 8, 1970 | FDA | BRISTOL MYERS SQUIBB | |
| April 28, 2004 | EMA | HRA Pharma Rare Diseases |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adrenal insufficiency | 147.60 | 53.20 | 43 | 1545 | 29878 | 90596981 |
| Off label use | 119.93 | 53.20 | 119 | 1469 | 1102133 | 89524726 |
| Adrenocortical insufficiency acute | 107.98 | 53.20 | 21 | 1567 | 2580 | 90624279 |
| Disease progression | 78.58 | 53.20 | 43 | 1545 | 156572 | 90470287 |
| Malignant neoplasm progression | 72.67 | 53.20 | 36 | 1552 | 106834 | 90520025 |
| Adrenocortical carcinoma | 63.52 | 53.20 | 8 | 1580 | 52 | 90626807 |
| Drug interaction | 62.93 | 53.20 | 46 | 1542 | 276407 | 90350452 |
| Precocious puberty | 57.43 | 53.20 | 9 | 1579 | 312 | 90626547 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adrenal insufficiency | 169.08 | 44.01 | 43 | 682 | 18881 | 42601729 |
| Adrenocortical carcinoma | 68.09 | 44.01 | 8 | 717 | 27 | 42620583 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adrenal insufficiency | 214.26 | 45.29 | 64 | 2156 | 42326 | 110544753 |
| Adrenocortical carcinoma | 110.23 | 45.29 | 14 | 2206 | 84 | 110586995 |
| Off label use | 106.46 | 45.29 | 139 | 2081 | 1500046 | 109087033 |
| Adrenocortical insufficiency acute | 104.93 | 45.29 | 23 | 2197 | 4417 | 110582662 |
| Malignant neoplasm progression | 81.58 | 45.29 | 48 | 2172 | 174519 | 110412560 |
| Disease progression | 60.06 | 45.29 | 45 | 2175 | 243989 | 110343090 |
| Drug clearance increased | 54.18 | 45.29 | 9 | 2211 | 393 | 110586686 |
| Febrile neutropenia | 47.79 | 45.29 | 44 | 2176 | 316723 | 110270356 |
| Neutropenia | 47.01 | 45.29 | 47 | 2173 | 374573 | 110212506 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XX23 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
| FDA MoA | N0000185506 | Cytochrome P450 3A4 Inducers |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
L01XX Other antineoplastic agents 33 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Carcinoma in situ of adrenal cortex | indication | 92526009 | |
| Hypercortisolism | off-label use | 47270006 | |
| Shock | contraindication | 27942005 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Traumatic injury | contraindication | 417746004 | |
| CNS Toxicity | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cytochrome P450 11B1, mitochondrial | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
| Cholesterol side-chain cleavage enzyme, mitochondrial | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.09 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.51 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.19 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.56 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.38 | DRUG MATRIX | |||||
| Acetyl-CoA acetyltransferase, mitochondrial | Enzyme | IC50 | 5.89 | CHEMBL | |||||
| Adrenodoxin, mitochondrial | Cytosolic other | WOMBAT-PK | |||||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 6.10 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.80 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4018140 | VUID |
| N0000146477 | NUI |
| D00420 | KEGG_DRUG |
| 4018140 | VANDF |
| C0026256 | UMLSCUI |
| CHEBI:6954 | CHEBI |
| CHEMBL1670 | ChEMBL_ID |
| DB00648 | DRUGBANK_ID |
| D008939 | MESH_DESCRIPTOR_UI |
| 4211 | PUBCHEM_CID |
| 6957 | IUPHAR_LIGAND_ID |
| 2597 | INN_ID |
| 78E4J5IB5J | UNII |
| 204257 | RXNORM |
| 1449 | MMSL |
| 5123 | MMSL |
| d01378 | MMSL |
| 002669 | NDDF |
| 26288002 | SNOMEDCT_US |
| 404865004 | SNOMEDCT_US |
| 78E4J5IB5J | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Lysodren | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68118-080 | TABLET | 500 mg | ORAL | NDA | 33 sections |
| Lysodren | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76336-080 | TABLET | 500 mg | ORAL | NDA | 33 sections |